Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce a COVID-19 vaccine.

The vaccine will be based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc’s prorietary Outer Membrane Vesicle (OMV) technology.

Earlier this year, Intravacc started working on the development of four candidate coronavirus vaccines based on three proprietary technologies: Vero cell, OMV and iBoost.

For this specific joint vaccine development, Intravacc combines its safe and immunogenic OMV delivery platform with S-proteins expressed by Celonic Group’s industry-leading CHOvolution mammalian cell expression system, in order to generate a highly effective and balanced B and T cell response against SARS-CoV-2.

Celonic Group will construct cell lines producing the  S-protein in high quantities and develop a GMP production process. Preclinical studies will start shortly to select the best candidate protein for the vaccine.

The collaboration aims to accelerate development of Intravacc’s COVID-19 OMV protein  vaccine, which is expected to enter clinical testing in 2021.

“Several studies have shown that OMVs have the ability to enhance the immune response and can be relatively easy formulated with target specific peptides and proteins,” said Intravcc CEO Dr Jan Groen.

“This, combined with the fact they can be quickly scaled-up for manufacturing, makes it an ideal suited platform under the current circumstances where quantity and speed are critical”

Dr Konstantin Matentzoglu, CEO of Celonic, added: “The novel vaccine has the potential to prevent morbidity and mortality of COVID-19. Together, we have an opportunity to make a difference in the lives of patients at this time of great need.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...

Search for new cancer treatments get £8m genetic boost

Projects to find new treatments for cancer, using whole genome sequencing, have received a £8 million funding boost from UK Research and Innovation (UKRI). Despite...

Mylan acquiring Aspen’s European thrombosis business

Mylan is expanding its complex injectables offering and presence in hospitals with the €641.9 million acquisition of Aspen Pharmacare's thrombosis business in Europe. The portfolio...

Related news

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...